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The chondroitin sulfate proteoglycans (CSPGs) aggrecan, versican, and brevican are large aggregating extracellular matrix
molecules that inhibit axonal growth of the mature central nervous system (CNS). ADAMTS proteoglycanases, including
ADAMTS4 and ADAMTS5, degrade CSPGs, representing potential targets for ameliorating axonal growth-inhibition by CSPG
accumulation after CNS injury. We investigated the proteolysis of CSPGs in mice homozygous for Adamts4 or Adamts5 null
alleles after spinal cord injury (SCI). ADAMTS-derived 50–60 kDa aggrecan and 50 kDa brevican fragments were observed in
Adamts4−/−, Adamts5−/−, and wt mice but not in the sham-operated group. By contrast Adamts4−/− and Adamts5−/− mice
were both protected from versican proteolysis with an ADAMTS-generated 70 kDa versican fragment predominately observed
in WT mice. ADAMTS1, ADAMTS9, and ADAMTS15 were detected by Western blot in Adamts4−/−mice’ spinal cords after SCI.
Immunohistochemistry showed astrocyte accumulation at the injury site.These data indicate that aggrecan and brevican proteolysis
is compensated in Adamts4−/− or Adamts5−/− mice by ADAMTS proteoglycanase family members but a threshold of versican
proteolysis is sensitive to the loss of a single ADAMTS proteoglycanase during SCI. We show robust ADAMTS activity after SCI
and exemplify the requirement for collective proteolysis for effective CSPG clearance during SCI.
1. Introduction
The extracellular matrix (ECM) is important for structural
and functional development and maintenance of the cen-
tral nervous system (CNS). The hyalectan (hyaluronan and
lectin) binding class of chondroitin sulfate proteoglycans
(CSPGs) comprises aggrecan, versican, neurocan, and brevi-
can, each sharing a common N-terminal G1 domain invari-
ably linked to hyaluronan, and aG3C-terminal domain [1, 2].
Large O-linked glycosaminoglycan (GAG) chains attached to
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serine or threonine residues modify several splice variants
of versican, aggrecan, brevican, and neurocan. Chondroitin
sulphate moieties covalently attached to GAG chains confer
a high negative charge attracting water into the tissue,
providing rigidity and structure. Digestion of GAG chains
using chondroitinase ABC creates a permissive media for
axonal regrowth, in turn promoting regain of function. On
the other hand, the loss of core proteins after chondroitinase
ABC digestion maintains an inhibitory habitat at the injury
site [1].
Adult mammalian CNS has poor plasticity to accom-
plish proper axon regeneration and sprouting. Glial scar
formation caused by the reactive astrocyte response after
traumatic injuries in the CNS is a major impediment to
axonal regeneration partly due to CSPG production that
is inhibitory for axonal regeneration [1]. Versican is pre-
dominately localized to nodes of Ranvier whilst aggrecan,
brevican, and neurocan are present in axonal coats [3–6].
Recently, aggrecan, versican, and brevican were shown to
inhibit axonal regeneration and myelination after neuronal
injury [4–6].These observations drew focus to the possibility
of promoting proteolysis of hyalectans to favor gain-of-
function after spinal cord injury.
ADAMTS4 and ADAMTS5 (aggrecanase-1 and aggrec-
anase-2, resp.) are the predominant enzymes in cartilage
breakdown [7, 8], although recent studies revealed signifi-
cant aggrecanolysis in articular cartilage of ADAMTS4 or
ADAMTS5 knockoutmice suggesting additional aggrecanase
activity by one or more members of the ADAMTS aggre-
canase family yet to be identified in the arthritic joint [9,
10]. Previous studies identified roles for ADAMTS4 and
ADAMTS5 in spinal cord pathology; however, their role
during spinal cord injury remains unclear. Tauchi et al. [6]
showed that ADAMTS4 promoted functional recovery after
SCI by cleaving CSPGs. We recently showed that Adamts1,
Adamts5, and Adamts9 mRNA expression were increased
in mice following SCI [5]; however, the significance of this
observation was not explored.
The biological importance of versican, a widely expressed
transitional matrix PG [11], and its cleavage by ADAMTS
aggrecanases is exemplified during developmental morpho-
genesis and reproduction. Despite ADAMTS5 single knock-
out mice being previously reported as phenotypically normal
[7, 8, 12], those mice present with limb and heart abnor-
malities [13–15] where a reduction or absence of versican
processing is also observed. An ADAMTS-generated N-
terminal versican fragment rescued the ADAMTS-deficient
limb-defect phenotype showing unequivocally that versican
processing was required for developmentalmorphogenesis of
the distal limb [15]. In ADAMTS1 knockout mice reduced or
absent versican processing is observed in ovarian follicles and
those mice have significantly lower fertility rates than wild-
type mice due to anovulation [16].
The fact that ADAMTS proteoglycanases confer their
substrate specificity towards the hyalectan class of CSPGs
makes them ideal candidate therapeutic targets to pursue
in SCI. The present study focused on ADAMTS4 and
ADAMTS5 because of their previously highlighted roles in
aggrecan and versican processing in contexts such as arthritis
progression and developmental morphogenesis. Here, we
report the proteolysis of three major substrates for these
enzymes in spinal cords of Adamts4−/− or Adamts5−/−mice
after spinal cord injury.
2. Material and Methods
2.1. Animals Experiments. Animal procedures were approved
by the Okayama University, Okayama, Japan Animal Ethics
Committee, in accordance with the International Care
and Use of Animals in Research guidelines. Adamts4
(B6.129P2-Adamts4tm1Dgen/J) and Adamts5 (B6.129P2-
Adamts5tm1Dgen/J) knockout mice were obtained from The
Jackson Laboratory and are previously described [15, 17].
Spinal cord injury was induced in mice as previously
described [5]. Briefly, mice were anesthetized with an I.P.
injection of 50mg/kg pentobarbital. Mice underwent a
single level laminectomy and the dura was exposed at the
middle thoracic level. A 3 g weight was dropped from 25mm
height using a modified NYU impactor to produce moderate
contusion (1.3mm) injury. This procedure was performed
in three groups of 7 mice, group 1: wild-type, group 2:
Adamts4−/−, and group 3: Adamts5−/−. Sham-operated (no
injury) mice were also used as control (𝑛 = 7). For the sham
group, only laminectomy was performed and surgical sites
were sutured in layers.
2.2. Protein Analysis. Central lesion points in spinal cords
were dissected 3mm in length. Protein was extracted using
a commercial kit (Cell lytic M Cell, sigma, St. Louis, MO).
Western blot analysis was performed on days 1 (aggrecan
and brevican) and 7 (versican and brevican) to examine their
degradation products in all experimental groups. Protein
concentration was determined using a Bradford assay kit
(Biorad). Ten𝜇g of total protein per experimental group
was boiled and electrophoresed on 4–15% sodium dodecyl
sulfate (SDS) reducing polyacrylamide gels. Proteins were
transferred onto nitrocellulose membranes (Millipore, Bil-
lerica, MA) and blocked with 5% skim-milk in PBS for 1 h.
After blocking, membranes were incubated overnight at 4∘C
with primary antibodies to analyze the proteoglycans that
are cleaved by ADAMTS activity during the injury phase
in vivo: anti-aggrecan NITEGE (Abcam, cat. no. ab3775),
a monoclonal antibody raised to the C-terminal neoepi-
tope NITEGE (mouse, clone BC-13), which recognizes the
aggrecanase generated C-terminal neoepitope EGE373↓374A
within the interglobular domain of cleaved aggrecan [8];
anti-versican DPEAAE (Abcam, cat. no. ab19345), a poly-
clonal antibody raised against the C-terminal neoepitope
DPEAAE, which recognizes the aggrecanase generated C-
terminal neoepitope DPEAAE441↓A442 at the N-terminus
of V0/V1 versican [18]; anti-brevican (Santa Cruz, cat no.
sc-20555), a goat polyclonal antibody raised against a pep-
tide mapped to the N-terminus of human brevican that
recognizes full length brevican and ADAMTS aggrecanase
generated C-terminal cleavage products [19]. Moreover, we
next analyzed ADAMTS1 (Abcam, ab. 28284), raised to an
epitope at the amino terminal end of ADAMTS1 after the
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Figure 1: Aggrecan cleavage in Adamts4−/− and Adamts5−/−mice
following SCI. Aggrecan fragments (∼50 and 60 kDa) detected with
the anti-NITEGE antibody are seen in wild-type, Adamts4−/−,
and Adamts5−/− mice 1 day after SCI (arrows, top panel). Lower
molecular weight species (∼25 kDa) are also seen in most groups
(asterisks, top panel). No aggrecanase activity was detected in sham-
operatedmice.𝛽-Actinwas used as a loading control (bottompanel).
second furin cleavage site in its propeptide, which detects
the active form and autocatalytically processed ADAMTS1
[20]; ADAMTS9 (Abcam, ab. 28279 and it was a kind gift
from Professor Suneel Apte) raised to the amino terminal end
of ADAMTS9 previously described as detecting full-length
ADAMTS9 [21]; and ADAMTS15 (Abcam, ab. 28516), raised
to the cysteine-rich domain of ADAMTS15 [22]. Secondary
antibodies conjugated with horseradish peroxidase followed
primary antibody incubations. Enhanced chemiluminescent
(ECL) substrate fromBiorad (USA)was used for visualization
of protein bands. Anti-𝛽-actin antibody (Abcam) was used as
a loading control.
2.3. Immunohistochemistry. Immunostaining was used to
evaluate the astrocyte response to SCI. Spinal cord tissue
was fixed with 4% paraformaldehyde for 20min at room
temperature, permeabilized for 10min with 0.1% Triton X-
100 in PBS, blocked with 4% skim milk (Thermo), and
then incubated for 2 h at room temperature with anti-glial
fibrillary acidic protein (GFAP) antibody (1 : 400; DakoCy-
tomation, Carpinteria, CA). The tissue sections were washed
in PBS Triton X-100 followed by incubation with goat anti-
rabbit antibody conjugated to Alexa 488 fluorophore (1 : 400;
Molecular Probes, Invitrogen). Nuclei were counterstained
with Hoechst for visualization. Images were captured on
Olympus BX51 microscope (Olympus Corporation).
3. Results and Discussion
3.1. Aggrecan Processing during SCI. Since we previously
showed significant upregulation of aggrecan mRNA at 1 day
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Figure 2: Versican cleavage in Adamts4−/− and Adamts5−/− mice
following SCI. Versican fragments (∼70 kDa) detected with the anti-
DPEAAE antibody are seen in wild-type but not Adamts4−/− and
Adamts5−/−mice 7 days after SCI (top panel, arrow).No versicanase
activity was detected in sham-operated mice. 𝛽-Actin was used as a
loading control (bottom panel).
post injury (dpi) [5], we examined aggrecanolysis at this
time point. Following SCI, we observed significant ADAMTS
generated aggrecan cleavage by Western blot analysis in
wild-type, Adamts4−/−, and Adamts5−/− mice (Figure 1). A
predominant∼60 kDa band, representing theG1-NITEGEN-
terminal aggrecan fragment generated by ADAMTS proteo-
glycanases, with an accompanying ∼50 kDa band that was
readily detectable in all cases except in the sham group
(Figure 1), clearly indicating that SCI was responsible for the
induction of aggrecan proteolysis. In addition, lower molec-
ular weight bands of ∼25 to ∼30 kDa were also differentially
observed between the sham and SCI groups (Figure 1). These
data suggested that ADAMTS4, ADAMTS5, or the other 5
members of the ADAMTS aggrecanase family (ADAMTS1,
ADAMTS8, ADAMTS9, ADAMTS15, and ADAMTS20)
might cooperate in aggrecan cleavage during spinal cord
injury.
3.2. Versican Processing during SCI. In contrast to aggre-
can, versican mRNA is significantly upregulated at 7 dpi
[5]. Western blot analysis on spinal cord protein lysate
from 7 dpi revealed the expected ADAMTS proteoglycanase
derived 70 kDa versican fragment representing the G1-
DPEAAE N-terminal region of V1 versican in the wild-
type group (Figure 2). However, in contrast to aggrecan at
1 dpi, little to no G1-DPEAAE fragments were observed in
either case of ADAMTS4 or ADAMTS5 knockout mice that
had undergone SCI. These data highlight the cooperative
nature of the ADAMTS proteoglycanase family to maintain
a threshold of versican cleavage during SCI, whereby neither
ADAMTS4 nor ADAMTS5, or the remaining ADAMTS
proteoglycanases, were able to collectivelymaintain threshold
versican cleavage in the absence of either ADAMTS4 or
ADAMTS5. In addition, we also observed an uncharac-
terized ∼37 kDa band using the anti-DPEAAE antibody
(see Figure 1 in supplementary materials available online
at http://dx.doi.org/10.1155/2014/693746) in all experimental
groups.
3.3. Brevican Processing during SCI. Western blot analysis
to investigate brevican processing was undertaken at both
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Figure 3: Brevican cleavage in Adamts4−/− and Adamts5−/− mice following SCI. Full-length brevican (∼145 kDa) and brevican fragments
(∼50 kDa) detected with the anti-brevican antibody are seen in wild-type,Adamts4−/−, andAdamts5−/−mice 1 and 7 days after SCI (arrows).
All groups showed diminished brevican cleavage at 7 days after injury. Minimal brevicanase activity was detected in sham-operated mice.
1 dpi and 7 dpi. Total brevican (∼145 kDa) and the ADAMTS
proteoglycanase generated 50 kDa brevican fragments were
observed at days 1 and 7 in wild-type and Adamts5−/− mice
(Figure 3), whilst Adamts4−/− mice showed total brevican
and the ADAMTS-generated brevican fragment (G1-AVESE)
[19] at 1 dpi and to a lesser extent total brevican and its
fragment at 7 dpi (Figure 3). Brevican cleavage was decreased
at day 7 in all groups (Figure 3).
3.4. Other ADAMTS Proteoglycanases during SCI. In the
absence of ADAMTS4 + ADAMTS5 double knockout mice,
we could not rule out the contribution to aggrecan and
brevican proteolysis by each other or additional ADAMTS
proteoglycanases. However, since aggrecanase activity was
clearly present in both ADAMTS4 and ADAMTS5 knockout
mice, we used Adamts4−/− mice to confirm the presence of
a subset of other ADAMTS proteoglycanases during spinal
cord injury. Western blot analysis using antibodies specific to
a subset of ADAMTS proteoglycanases showed the presence
of ADAMTS1, ADAMTS9, and ADAMTS15 in spinal cord
tissue (Figures 4(a), 4(b), and 4(c), resp.). An 85 kDa band
representing the active form of ADAMTS1 [23] as well as
a smaller ∼35 kDa fragment representing autocatalysis of
ADAMTS1 [23] was observed at days 1 and 7 of spinal
cord injury (Figure 4(a)). A ∼180 kDa band representing
the zymogen (unprocessed) form of ADAMTS9 [24] was
observed in all experimental groups (Figure 4(b)), and a ∼
130 kDa band representing the zymogen (unprocessed) form
of ADAMTS15 [22] was also observed in all experimental
groups (Figure 4(c)). Lower molecular weight bands were
also observed in both cases of ADAMTS9 and ADAMTS15
(Figures 4(b) and 4(c), resp.—asterisks), whichmay represent
autocatalysis of those ADAMTS proteoglycanases [22, 24].
Although all three ADAMTS proteoglycanases were present
in ADAMTS4 knockout mice, the most likely candidate
for compensatory aggrecanase activity is ADAMTS1 since
it was the only ADAMTS shown in its active form, and
it robustly appeared in the case of spinal cord injury but
not in the sham-operated group (Figure 4(a)). In addition,
immunostaining demonstrated astrocyte accumulation at the
injury site compared to normal tissue (Figure 4(d)), which
could represent the source of ADAMTS proteoglycanase
expression.
Spinal cord injury is a severe and essentially irreversible
process characterized by excessive CSPGs accumulation and
the enzymatic removal of chondroitin sulfate at the site of
SCI can promote a regenerative process. In this current
study, we induced SCI in mice and examined the activity
of the ADAMTS proteoglycanases, a family of extracellular
proteinases that cleave hyalectan substrates relevant to the
spinal cord, namely, aggrecan, brevican, and versican, and
could therefore be relevant to the regeneration process.
We previously demonstrated that Adamts1, Adamts5, and
Adamts9 mRNA expressions were significantly increased in
the same SCI mouse model in wild-type mice and suggested
that aggrecan, versican, and brevican degradation may be
mediated by these and otherADAMTSproteoglycanases pro-
duced by reactive astrocytes after SCI [5]. Here, we extended
the previous study to utilize Adamts4−/− or Adamts5−/−
mice and studied the consequence of SCI on proteolytic activ-
ity upon three major hyalectans that represent predominate
sources of CSPGs in the spinal cord.
Aggrecan cleavagewas readily detectable in injured spinal
cords of both Adamts4−/− and Adamts5−/− mice. Since
both ADAMTS4 and ADAMTS5 are strong aggrecanases
[25, 26], this result was perhaps unsurprising. Although
double Adamts4−/− and Adamts5−/− mice are required to
reconcile whether one aggrecanase is compensating for the
other in response to SCI, it is apparent from this current
study that robust aggrecanase remodeling can occur in the
BioMed Research International 5
M
(Days)
Sham 1 7
∗
75
50
37
(k
D
a)
IB: anti-ADAMTS1
IB: anti-𝛽-actin
Adamts4−/−
(a)
(Days)
Sham 1 7
∗
∗
150
100
75
50
37
(k
D
a)
Z
IB: anti-ADAMTS9
IB: anti-𝛽-actin
Adamts4−/−
(b)
(Days)
Sham 1 7
∗
150
100
75
50
(k
D
a)
IB: anti-ADAMTS15
IB: anti-𝛽-actin
Z
Adamts4−/−
(c)
Sham SCI
(d)
Figure 4: ADAMTS proteoglycanases are expressed during SCI. (a) ADAMTS1 is expressed in spinal cord tissue ofAdamts4−/−mice 1 and 7
days after injury, m = mature, asterisk = autocatalytic fragment. (b) ADAMTS9 is expressed in spinal cord tissue of Adamts4−/−mice in the
sham-operated group 1 and 7 days after injury, z = zymogen (inactive), asterisks = uncharacterized fragments. (c) ADAMTS15 is expressed in
spinal cord tissue ofAdamts4−/−mice in the sham-operated group 1 and 7 days after injury, z = zymogen (inactive), asterisk = uncharacterized
fragments. In all cases 𝛽-actin was used as a loading control (bottom panels). (d) Spinal cord injury triggered astrocyte accumulation (reactive
astrocytes) at the injury site compared with sham-operated mice. Red = astrocyte, blue = nucleus. Scale bar = 50𝜇m.
absence of eitherADAMTS4 orADAMTS5. In previous stud-
ies examining aggrecan destruction utilizing ADAMTS4 +
ADAMTS5 double knockout mice, significant aggrecanolysis
has been observed [9, 27] suggesting that other ADAMTS
aggrecanases can contribute to aggrecan breakdown in addi-
tion to ADAMTS4 and ADAMTS5.
Versican is normally expressed in the mouse brain;
its upregulation inhibits axonal regeneration after CNS
injury [4]. In this current study, we observed ADAMTS
proteoglycanase-specific V1 versican cleavage at DPEA-
AE441↓A442 in response to SCI in wild-type mice; however,
Adamts4−/− or Adamts5−/− mice were largely protected.
Several cases of severely reduced or absent versican prote-
olysis in single knockout mice have been reported during
development including cardiacmorphogenesis inADAMTS5
knockout mice embryos [13], melanoblast colonization in
ADAMTS20 knockout mice [28], and folliculogenesis in
ADAMTS1 knockout mice [16]. To this end, we conclude
that the absence of either ADAMTS4 or ADAMTS5, two
of the strongest versicanases [29], significantly reduced the
threshold of V1 versican proteolysis in SCI. ADAMTS pro-
teoglycanases act cooperatively to process versican during
several developmental processes in the mouse; ADAMTS5,
ADAMTS9, and ADAMTS20 are required for interdigital
web regression during limb formation, and ADAMTS9 and
ADAMTS20 are required for palatal shelf closure during
secondary palate formation [15, 30]. Thus it is not unrea-
sonable to conclude this to be cooperatively required in
neuronal tissue that is undergoing regeneration after injury.
Although our major focus was the DPEAAE441↓A442 cleav-
age site targeted by ADAMTS proteoglycanases in V0/V1
versican, the V2 versican splice variant is the major source
of versican in the CNS [31]. However the V2 splice variant
does not possess the GAG-𝛽 domain containing the well-
described ADAMTS cleavage site, although it is remodeled
by ADAMTS proteoglycanases at an alternate site [31] not
examined in detail in this current study.
Brevican, unlike versican and aggregan, is specifically
expressed in the CNS. In this study, we showed that prote-
olytic processing of brevican was similar to that of aggrecan
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with significant processing occurring in both Adamts4−/−
and Adamts5−/− mice with an interesting caveat that its
proteolysis was markedly reduced at 7 dpi in Adamts5−/−
mice and essentially absent at this time-point in Adamts4−/−
mice. Both ADAMTS4 and ADAMTS5 have previously been
reported to proteolytically process brevican andAdamts5was
found to be overexpressed in glioblastoma tissue compared to
normal brain tissue [32].
We demonstrated the presence of ADAMTS1, AD-
AMTS9, and ADAMTS15 proteins in spinal cords of
ADAMTS4 knockout mice and confirmed the active form
of one of those proteoglycanases, ADAMTS1, during spinal
cord injury. Proteolysis of aggrecan is exerted by ADAMTS
proteases including ADAMTS1 [23], ADAMTS4 [33],
ADAMTS5 [34], and ADAMTS8 [35] in cartilage tissue.
The ADAMTSs that cleave aggrecan are less studied in CNS
injury, and especially little is known in the context of SCI.
However, accumulating evidence points out their roles in
CNS pathologies. ADAMTS1 deficient mice showed efficient
brevican and versican V2 cleavage in frontal cortex [36];
however, in this current study its active form was noticeably
absent in the sham groups but specifically expressed during
spinal cord injury in ADAMTS4 knockout mice suggesting
it to be a major contributor of aggrecanase activity during
this process.
We focused this study onADAMTS4 andADAMTS5, the
major aggrecanases under investigation in cartilage destruc-
tion in arthritis. ADAMTS4 was first cloned from human
brain [37] and is responsive to several CNS conditions such
as beta-amyloid, which induces ADAMTS4 upregulation in
rat astrocytes [38].Adamts4, along withAdamts1mRNA, was
markedly elevated in the hippocampus of rats in response
to kainate-induced excitotoxic lesion [39] while Adamts1
expression also increased in a rat model of middle cerebral
artery occlusion, [40]. ADAMTS proteoglycanases may also
interact with other pathways; for example, ADAMTS4 can
signal through MAP ERK1/2 to promote neurite overgrowth
independent of its proteolytic activity [41].
The present study was performed in single knockout
mice where proteolysis of aggrecan and brevican was indi-
cated. Given that ADAMTS activity likely benefits neurite
outgrowth after CNS injury [5, 6], onemight hypothesize that
abolishing the activity of two ormoreADAMTS aggrecanases
could adversely affect the recovery process after CNS injury.
Although studies in double knockout mice are feasible
given that ADAMTS4 + ADAMTS5 knockout mice are
reproductively viable, previous studies suggest that additional
aggrecan-degrading activity is present in those mice in
pathological processes [27]. However, sequentially knocking
out additional ADAMTS aggrecanases in mice is not viable
due to the embryonic lethality of Adamts9−/−mice [30], and
Adamts1 and Adamts5 are separated by only 60 kb on mouse
chromosome 16 [42], giving a low probability of segregation
of these two Adamts genes during meiosis, making it difficult
to generate ADAMTS1 + ADAMTS5 knockout mice using
standard Mendelian genetic approaches. Taken together, our
findings suggest that othermembers of the ADAMTS proteo-
glycanase family, such as ADAMTS1, may be responsible for
turnover of aggrecan, versican, and brevican cleavage in the
mouse spinal cord.
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